Filing summary
Entity and period: The supplied filing is Flora Growth Corp.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 31, 2023. This does not match the request metadata naming Zerostack Corp. or “2022 Q4”; the filing reports full-year results for Flora Growth, not Zerostack.
Business context
Flora is a multinational cannabis and pharmaceutical company operating across consumer brands, commercial and wholesale distribution, and pharmaceuticals. Its activities span the United States, Colombia, and Europe. The year included acquisitions of JustCBD and Franchise Global Health; Vessel was acquired in 2021.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | 2022 | 2021 |
|---|---|---|
| Revenue | $37.2 | $9.0 |
| Gross profit / margin | $14.4 / 39% | $2.4 / 27% |
| Operating loss | $(53.3) | $(19.0) |
| Net loss | $(52.6) | $(21.4) |
| Adjusted EBITDA (non-GAAP) | $(18.3) | $(16.5) |
| Operating cash flow | $(15.9) | $(20.9) |
- Revenue growth was chiefly acquisition-driven: JustCBD contributed $32.2 million and Franchise Global Health $0.1 million after its late-December acquisition. House of Brands revenue was $40.5 million before $6.1 million of intersegment eliminations. Pharmaceuticals revenue declined to $2.5 million from $3.2 million; commercial and wholesale revenue was $0.2 million.
- Net loss widened, principally due to $26.2 million of goodwill and other asset impairments and higher operating expenses. Goodwill impairment was $25.5 million, including the full $19.7 million assigned to Vessel and $5.4 million for JustCBD.
- Cash and cash equivalents fell to $9.5 million from $37.6 million. Investing cash outflow was $15.8 million; financing provided $4.4 million. Year-end working capital was $13.7 million.
- Year-end total assets were $81.0 million, total liabilities $24.6 million, and shareholders’ equity $56.4 million. Debt included a €1.0 million credit facility, reported as approximately $1.1 million, secured by receivables. The facility’s maturity was extended in January 2023; operating lease liabilities totaled $3.1 million.
- Trade receivables were $6.8 million net of a $3.0 million expected-credit-loss allowance; inventory was $10.1 million. The company recorded $1.1 million of inventory write-downs in 2022.
Changes, outlook, risks, and unusual items
- Management and the auditor identified substantial doubt about Flora’s ability to continue as a going concern. Management said additional capital may be required and described cost reductions and potential equity, debt, strategic-partner, or credit financing; availability on acceptable terms is uncertain.
- No specific company revenue or earnings guidance is provided. Management described plans to scale production and pursue international distribution. Flora Lab 4 was completed after year-end; its GMP inspection and anticipated sales depended on regulatory certification and approvals.
- Flora reported a $3.0 million provision for legal disputes and a $1.8 million estimated sales-tax liability. Some acquired Franchise-related claims are covered by an indemnity capped at $5.0 million; the filing notes that claims against the former entities exceed that cap, while management estimated covered losses would not exceed it. A separate claim seeking 3.0 million pre-split shares was disputed and no liability was accrued.
- Nasdaq had notified Flora of a minimum-bid-price deficiency. An extension gave the company until July 3, 2023 to regain compliance, with a reverse split identified as a possible remedy.
- Disclosure controls and internal control over financial reporting were ineffective at year-end. The material weakness concerning goodwill impairment testing and purchase-price allocations remained unremediated; weaknesses relating to receivables, revenue, and inventory procedures were reported as remediated.
- Other significant risks include changing cannabis regulation, U.S. federal prohibition of THC cannabis, dependence on Colombian licenses and operations, access to financing and banking, product-liability and quality risks, foreign-exchange exposure, and acquisition integration. The company did not hedge foreign-currency exposure.
Most important facts for investors to verify
- Flora’s near-term cash runway, payment obligations, and ability to raise capital without substantial dilution or curtailing operations.
- Whether the company regained Nasdaq’s bid-price compliance by the July 3, 2023 deadline.
- Cash conversion and underlying performance excluding acquisitions, impairments, and other adjustments; review the non-GAAP Adjusted EBITDA reconciliation.
- Recoverability of goodwill and acquired intangible assets, particularly JustCBD, and progress in remediating the remaining control weakness.
- Collection of receivables and indemnification claims, resolution of litigation and sales-tax matters, and completion of Colombian and German regulatory approvals.
- Share-count and dilution effects: 135.6 million shares were reported outstanding at December 31, 2022; 136.9 million were reported as outstanding on March 22, 2023.